登录 注册 会员服务 联系我们

Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors

  • Published:2017-09-18 Issue:11 Volume:19 Page:
  • ISSN:1523-3790
  • Container-title:Current Oncology Reports
  • language:en
  • Short-container-title:Curr Oncol Rep

Author:

Carmona-Bayonas Alberto, ,Jiménez-Fonseca Paula,Custodio Ana,Grande Enrique,Capdevila Jaume,López Carlos,Teule Alex,Garcia-Carbonero Rocío

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Reference95 articles.

1. Öberg K, Knigge U, Kwekkeboom D, Perren A, ESMO Guidelines Working Group, Oberg K, et al. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: Off J Eur Soc Med Oncol, ESMO [Internet]. 2012;23(Suppl 7):vii124–30. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22997445

2. Hallet J, Law CHL, Cukier M, Saskin R, Liu N, Singh S. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epidemiology, metastatic presentation, and outcomes. Cancer. 2015;121:589–97. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25312765

3. • Caplin ME, Pavel M, Cwikła JB, Phan AT, Raderer M, Sedláčková E, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014;371:224–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25014687 . The CLARINET phase III trial enrolled patients with advanced, Ki-67 <10%, non-functional, octreotide scan positive GEP-NETs. Subjects were randomly assigned to receive lanreotide 120 mg once every four weeks or placebo. Treatment with lanreotide significantly prolonged PFS over placebo (median not reached versus 18 months, respectively, HR=0.47, p=0.0002).

4. Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011a;364:501–13.

5. • Yao JC, Fazio N, Singh S, Buzzoni R, Carnaghi C, Wolin E, et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. Lancet. 2016;387:968–77. This phase III trial (RADIANT-4) enrolled 302 patients with lung/gastrointestinal NETs. The participants were randomized 2:1 to everolimus 10 mg/day plus best supportive care versus placebo plus best supportive care. At follow-up, there was an increase in progression-free survival in the everolimus group, with HR 0.48 (95% CI 0.28-0.64, p<0.001).
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3